Hodgkin’s Lymphoma

October 3, 2019

Adcetris Most Effective in Chemo-sensitive Patients, or as Consolidation Therapy After Stem Cell Transplant, Study Finds

News

Treatment with Adcetris (brentuximab vedotin) is most effective in people with relapsed or refractory Hodgkin’s lymphoma who have chemotherapy-sensitive disease, and when used as consolidation therapy immediately after stem cell ... Read more

July 19, 2019July 19, 2019

Affimed Trial Updates Support AFM13 Use for Certain CD30-positive Lymphomas

News

Updated results from two clinical trials support the potential of AFM13, an investigational immunotherapy being developed by Affimed, in combination with Merck‘s Keytruda (pembrolizumab) for patients with Hodgkin’s lymphoma, or ... Read more

March 21, 2019

PD-L1 Levels, Response to Tecentriq Linked in Younger Cancer Patients

News

Children, adolescents, and young adults with relapsed or refractory cancers — particularly those with lymphoma — have better responses to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) if they have high ... Read more

March 7, 2019

$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies

News

The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to shut ... Read more

March 5, 2019

PET Monitoring Can Be Used to Tailor Hodgkin’s Treatment, Trial Suggests

News

Monitoring Hodgkin’s lymphoma patients with positron-emission tomography (PET) scans during chemotherapy can help identify those who respond early to a more intense chemotherapy regimen and switch them to a softer, ... Read more

February 15, 2019

European Commission Approves Adcetris/Chemo Combo for Some Hodgkin’s

News

The European Commission has approved the used of Adcetris (brentuximab vedotin) in combination with standard chemotherapy for the initial treatment of advanced CD30-positive Hodgkin’s lymphoma patients in the European Union, Norway, Liechtenstein and Iceland. The approval, ... Read more

January 22, 2019

Childhood Hodgkin’s Lymphoma Survivors At Higher Risk for Cancer Later in Life, Study Shows

News

Survivors of childhood Hodgkin’s lymphoma are 14 times more likely to develop a subsequent solid tumor than the general population, and this risk remains high for several decades post-diagnosis, a ... Read more

January 2, 2019

Immune Checkpoint Inhibitors Make Lymphoma Respond Better to Future Treatment, Studies Suggest

News

Patients with both Hodgkin’s and non-Hodgkin’s lymphoma who receive immune checkpoint inhibitors as their second-line or later treatment might respond better to their subsequent therapy, even if they failed to ... Read more

December 18, 2018

Depleting White Blood Cells Improves Response to CAR T-cell Therapy in Heavily Treated Patients, Trial Shows

News

A preconditioning chemotherapy regimen given before CD30.CAR-T therapy — a CAR T-cell therapy directed at CD30-positive cancers — seems to improve heavily treated lymphoma patients’ responses to the treatment, a Phase 1/2 ... Read more

October 3, 2018

Adcetris-Gemcitabine Combo Eliminates Cancer in Two-thirds of Hodgkin’s Lymphoma Patients in Phase 1/2 Trial

News

A combination of Adcetris (brentuximab vedotin) and the chemotherapy gemcitabine completely eliminated the tumors in two out of three children and young adults with Hodgkin’s lymphoma in a Phase 1/2 ... Read more